Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05498597
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:39:31.413616+00:00
Published At
2023-10-19T00:00:00+00:00
Record Updated At
2023-10-19
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Advanced Solid Tumor", "Advanced Cancer", "Advanced Carcinoma", "Ovarian Cancer", "Ovarian Carcinoma", "Ovarian Epithelial Cancer", "Ovarian Endometrioid Adenocarcinoma", "Endometrial Cancer", "Endometrial Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Endometrial Endometrioid Adenocarcinoma", "Endometrial Clear Cell Adenocarcinoma", "Lung Adenocarcinoma", "Triple Negative Breast Cancer", "Pancreatic Ductal Adenocarcinoma", "Malignant Pleural Mesothelioma", "Ovarian Clear Cell Carcinoma", "Ovarian Clear Cell Adenocarcinoma", "Ovarian Mucinous Adenocarcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-10-19"
protocolSection.identificationModule.nctId
"NCT05498597"
protocolSection.identificationModule.officialTitle
"First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours"
protocolSection.statusModule.overallStatus
"UNKNOWN"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Advanced Solid Tumor (protocolSection.conditionsModule.conditions)
  • Advanced Cancer (protocolSection.conditionsModule.conditions)
  • Advanced Carcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Ovarian Carcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Epithelial Cancer (protocolSection.conditionsModule.conditions)
  • Ovarian Endometrioid Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Endometrial Cancer (protocolSection.conditionsModule.conditions)
  • Endometrial Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Endometrial Serous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Endometrial Endometrioid Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Endometrial Clear Cell Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Lung Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Triple Negative Breast Cancer (protocolSection.conditionsModule.conditions)
  • Pancreatic Ductal Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Malignant Pleural Mesothelioma (protocolSection.conditionsModule.conditions)
  • Ovarian Clear Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Clear Cell Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Mucinous Adenocarcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.